PMID- 22249517
OWN - NLM
STAT- MEDLINE
DCOM- 20120809
LR  - 20220408
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
VI  - 8
IP  - 5
DP  - 2012 Jan 17
TI  - Bone, sweet bone--osteoporotic fractures in diabetes mellitus.
PG  - 297-305
LID - 10.1038/nrendo.2011.233 [doi]
AB  - Diabetes mellitus adversely affects the skeleton and is associated with an 
      increased risk of osteoporosis and fragility fractures. The mechanisms underlying 
      low bone strength are not fully understood but could include impaired accrual of 
      peak bone mass and diabetic complications, such as nephropathy. Type 1 diabetes 
      mellitus (T1DM) affects the skeleton more severely than type 2 diabetes mellitus 
      (T2DM), probably because of the lack of the bone anabolic actions of insulin and 
      other pancreatic hormones. Bone mass can remain high in patients with T2DM, but 
      it does not protect against fractures, as bone quality is impaired. The class of 
      oral antidiabetic drugs known as glitazones can promote bone loss and 
      osteoporotic fractures in postmenopausal women and, therefore, should be avoided 
      if osteoporosis is diagnosed. A physically active, healthy lifestyle and 
      prevention of diabetic complications, along with calcium and vitamin D repletion, 
      represent the mainstay of therapy for osteoporosis in patients with T1DM or T2DM. 
      Assessment of BMD and other risk factors as part of the diagnostic procedure can 
      help design tailored treatment plans. All osteoporosis drugs seem to be effective 
      in patients with diabetes mellitus. Increased awareness of osteoporosis is needed 
      in view of the growing and aging population of patients with diabetes mellitus.
FAU - Hamann, Christine
AU  - Hamann C
AD  - Department of Orthopedics, Dresden Technical University Medical Center, 
      Fetscherstrasse 74, 01307 Dresden, Germany.
FAU - Kirschner, Stephan
AU  - Kirschner S
FAU - Gunther, Klaus-Peter
AU  - Gunther KP
FAU - Hofbauer, Lorenz C
AU  - Hofbauer LC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120117
PL  - England
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
RN  - 0 (Thiazolidinediones)
SB  - IM
MH  - Animals
MH  - Bone Density/drug effects
MH  - Diabetes Mellitus, Type 1/*complications/metabolism
MH  - Diabetes Mellitus, Type 2/*complications/*metabolism
MH  - Humans
MH  - Osteoporosis/drug therapy/metabolism
MH  - Osteoporotic Fractures/*etiology/*metabolism
MH  - Thiazolidinediones/adverse effects/therapeutic use
EDAT- 2012/01/18 06:00
MHDA- 2012/08/10 06:00
CRDT- 2012/01/18 06:00
PHST- 2012/01/18 06:00 [entrez]
PHST- 2012/01/18 06:00 [pubmed]
PHST- 2012/08/10 06:00 [medline]
AID - nrendo.2011.233 [pii]
AID - 10.1038/nrendo.2011.233 [doi]
PST - epublish
SO  - Nat Rev Endocrinol. 2012 Jan 17;8(5):297-305. doi: 10.1038/nrendo.2011.233.